Cellular Dynamics International this week said that it will use its cell-based assays to screen certain Roche drug candidates for cardiotoxicity.
 
Under the terms of the agreement, Roche will supply CDI with two sets of 25 well-characterized kinase inhibitors to validate CDI’s current crop of toxicology products and services, a Roche official told CBA News this week. CDI will test those compounds using human cardiomyocytes derived from human embryonic stem cells.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.